Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) Stock Competitors & Peer Comparison
See AUROPHARMA.NS's competitors and their performance on the NSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AUROPHARMA.NS and its NSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AUROPHARMA.NS | ₹1,688.90 | +0.72% | 963.7B | 26.17 | ₹64.00 | N/A |
| SUNPHARMA.NS | ₹1,789.80 | -0.62% | 4.3T | 34.57 | ₹51.48 | +0.90% |
| SUNPHARMA.BO | ₹1,787.80 | -1.23% | 4.3T | 34.94 | ₹51.00 | +0.90% |
| DIVISLAB.BO | ₹9,357.40 | +0.68% | 2.5T | 83.61 | ₹110.19 | +0.33% |
| DIVISLAB.NS | ₹9,350.50 | +1.10% | 2.4T | 83.49 | ₹110.15 | +0.33% |
| TORNTPHARM.BO | ₹4,762.20 | +0.01% | 1.8T | 72.16 | ₹65.90 | +0.80% |
| TORNTPHARM.NS | ₹4,766.60 | -0.01% | 1.8T | 71.50 | ₹66.74 | +0.80% |
| ZYDUSLIFE.BO | ₹1,151.10 | +0.51% | 1.1T | 26.81 | ₹42.46 | +0.09% |
| ZYDUSLIFE.NS | ₹1,149.00 | +0.29% | 1.1T | 26.67 | ₹42.71 | +0.09% |
| CIPLA.BO | ₹1,334.00 | -0.95% | 1.1T | 31.99 | ₹41.70 | +0.97% |
Stock Comparison
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA.NS)
AUROPHARMA.NS vs SUNPHARMA.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SUNPHARMA.NS trades at ₹1,789.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SUNPHARMA.NS's P/E ratio is 34.57. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUNPHARMA.NS's competition here
Sun Pharmaceutical Industries Limited (BSE: SUNPHARMA.BO)
AUROPHARMA.NS vs SUNPHARMA.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SUNPHARMA.BO trades at ₹1,787.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SUNPHARMA.BO's P/E ratio is 34.94. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUNPHARMA.BO's competition here
Divi's Laboratories Limited (BSE: DIVISLAB.BO)
AUROPHARMA.NS vs DIVISLAB.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, DIVISLAB.BO has a market cap of 2.5T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while DIVISLAB.BO trades at ₹9,357.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas DIVISLAB.BO's P/E ratio is 83.61. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to DIVISLAB.BO's ROE of +0.18%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to DIVISLAB.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check DIVISLAB.BO's competition here
Divi's Laboratories Limited (NSE: DIVISLAB.NS)
AUROPHARMA.NS vs DIVISLAB.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, DIVISLAB.NS has a market cap of 2.4T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while DIVISLAB.NS trades at ₹9,350.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas DIVISLAB.NS's P/E ratio is 83.49. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to DIVISLAB.NS's ROE of +0.18%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to DIVISLAB.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check DIVISLAB.NS's competition here
Torrent Pharmaceuticals Limited (BSE: TORNTPHARM.BO)
AUROPHARMA.NS vs TORNTPHARM.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, TORNTPHARM.BO has a market cap of 1.8T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while TORNTPHARM.BO trades at ₹4,762.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas TORNTPHARM.BO's P/E ratio is 72.16. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to TORNTPHARM.BO's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to TORNTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check TORNTPHARM.BO's competition here
Torrent Pharmaceuticals Limited (NSE: TORNTPHARM.NS)
AUROPHARMA.NS vs TORNTPHARM.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, TORNTPHARM.NS has a market cap of 1.8T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while TORNTPHARM.NS trades at ₹4,766.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas TORNTPHARM.NS's P/E ratio is 71.50. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to TORNTPHARM.NS's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to TORNTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check TORNTPHARM.NS's competition here
Zydus Lifesciences Limited (BSE: ZYDUSLIFE.BO)
AUROPHARMA.NS vs ZYDUSLIFE.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ZYDUSLIFE.BO trades at ₹1,151.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ZYDUSLIFE.BO's P/E ratio is 26.81. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ZYDUSLIFE.BO's ROE of +0.16%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ZYDUSLIFE.BO's competition here
Zydus Lifesciences Limited (NSE: ZYDUSLIFE.NS)
AUROPHARMA.NS vs ZYDUSLIFE.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ZYDUSLIFE.NS trades at ₹1,149.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ZYDUSLIFE.NS's P/E ratio is 26.67. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ZYDUSLIFE.NS's ROE of +0.16%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ZYDUSLIFE.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ZYDUSLIFE.NS's competition here
Cipla Limited (BSE: CIPLA.BO)
AUROPHARMA.NS vs CIPLA.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, CIPLA.BO has a market cap of 1.1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while CIPLA.BO trades at ₹1,334.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas CIPLA.BO's P/E ratio is 31.99. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to CIPLA.BO's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to CIPLA.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check CIPLA.BO's competition here
Cipla Limited (NSE: CIPLA.NS)
AUROPHARMA.NS vs CIPLA.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, CIPLA.NS has a market cap of 1.1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while CIPLA.NS trades at ₹1,338.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas CIPLA.NS's P/E ratio is 32.03. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to CIPLA.NS's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to CIPLA.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check CIPLA.NS's competition here
Laurus Labs Limited (NSE: LAURUSLABS.NS)
AUROPHARMA.NS vs LAURUSLABS.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, LAURUSLABS.NS has a market cap of 1.1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while LAURUSLABS.NS trades at ₹2,018.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas LAURUSLABS.NS's P/E ratio is 97.31. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to LAURUSLABS.NS's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to LAURUSLABS.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check LAURUSLABS.NS's competition here
Laurus Labs Limited (BSE: LAURUSLABS.BO)
AUROPHARMA.NS vs LAURUSLABS.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, LAURUSLABS.BO has a market cap of 1.1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while LAURUSLABS.BO trades at ₹2,014.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas LAURUSLABS.BO's P/E ratio is 96.70. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to LAURUSLABS.BO's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to LAURUSLABS.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check LAURUSLABS.BO's competition here
Mankind Pharma Limited (BSE: MANKIND.BO)
AUROPHARMA.NS vs MANKIND.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while MANKIND.BO trades at ₹2,500.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas MANKIND.BO's P/E ratio is 47.44. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to MANKIND.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check MANKIND.BO's competition here
Mankind Pharma Limited (NSE: MANKIND.NS)
AUROPHARMA.NS vs MANKIND.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while MANKIND.NS trades at ₹2,498.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas MANKIND.NS's P/E ratio is 47.43. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to MANKIND.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check MANKIND.NS's competition here
Dr. Reddy's Laboratories Limited (BSE: DRREDDY.BO)
AUROPHARMA.NS vs DRREDDY.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, DRREDDY.BO has a market cap of 1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while DRREDDY.BO trades at ₹1,210.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas DRREDDY.BO's P/E ratio is 30.40. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to DRREDDY.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check DRREDDY.BO's competition here
Dr. Reddy's Laboratories Limited (NSE: DRREDDY.NS)
AUROPHARMA.NS vs DRREDDY.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, DRREDDY.NS has a market cap of 1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while DRREDDY.NS trades at ₹1,210.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas DRREDDY.NS's P/E ratio is 30.29. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to DRREDDY.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check DRREDDY.NS's competition here
Aurobindo Pharma Limited (BSE: AUROPHARMA.BO)
AUROPHARMA.NS vs AUROPHARMA.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, AUROPHARMA.BO has a market cap of 960.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while AUROPHARMA.BO trades at ₹1,690.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas AUROPHARMA.BO's P/E ratio is 26.09. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AUROPHARMA.BO's competition here
Lupin Limited (NSE: LUPIN.NS)
AUROPHARMA.NS vs LUPIN.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, LUPIN.NS has a market cap of 919.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while LUPIN.NS trades at ₹2,024.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas LUPIN.NS's P/E ratio is 15.79. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to LUPIN.NS's ROE of +0.26%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check LUPIN.NS's competition here
Lupin Limited (BSE: LUPIN.BO)
AUROPHARMA.NS vs LUPIN.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, LUPIN.BO has a market cap of 916.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while LUPIN.BO trades at ₹2,015.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas LUPIN.BO's P/E ratio is 15.78. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to LUPIN.BO's ROE of +0.26%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check LUPIN.BO's competition here
Glenmark Pharmaceuticals Limited (BSE: GLENMARK.BO)
AUROPHARMA.NS vs GLENMARK.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GLENMARK.BO has a market cap of 659.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GLENMARK.BO trades at ₹2,286.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GLENMARK.BO's P/E ratio is 35.82. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GLENMARK.BO's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GLENMARK.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLENMARK.BO's competition here
Glenmark Pharmaceuticals Limited (NSE: GLENMARK.NS)
AUROPHARMA.NS vs GLENMARK.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GLENMARK.NS has a market cap of 647.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GLENMARK.NS trades at ₹2,294.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GLENMARK.NS's P/E ratio is 37.62. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GLENMARK.NS's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GLENMARK.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLENMARK.NS's competition here
Alkem Laboratories Limited (NSE: ALKEM.NS)
AUROPHARMA.NS vs ALKEM.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ALKEM.NS has a market cap of 620.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ALKEM.NS trades at ₹5,245.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ALKEM.NS's P/E ratio is 28.74. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ALKEM.NS's ROE of +0.16%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ALKEM.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ALKEM.NS's competition here
Alkem Laboratories Limited (BSE: ALKEM.BO)
AUROPHARMA.NS vs ALKEM.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ALKEM.BO has a market cap of 617.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ALKEM.BO trades at ₹5,237.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ALKEM.BO's P/E ratio is 28.65. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ALKEM.BO's ROE of +0.16%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ALKEM.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ALKEM.BO's competition here
Ipca Laboratories Limited (BSE: IPCALAB.BO)
AUROPHARMA.NS vs IPCALAB.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, IPCALAB.BO has a market cap of 498.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while IPCALAB.BO trades at ₹1,940.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas IPCALAB.BO's P/E ratio is 36.86. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to IPCALAB.BO's ROE of +0.16%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to IPCALAB.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check IPCALAB.BO's competition here
Ipca Laboratories Limited (NSE: IPCALAB.NS)
AUROPHARMA.NS vs IPCALAB.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, IPCALAB.NS has a market cap of 495.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while IPCALAB.NS trades at ₹1,941.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas IPCALAB.NS's P/E ratio is 36.65. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to IPCALAB.NS's ROE of +0.16%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to IPCALAB.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check IPCALAB.NS's competition here
Gland Pharma Limited (NSE: GLAND.NS)
AUROPHARMA.NS vs GLAND.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GLAND.NS has a market cap of 480.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GLAND.NS trades at ₹2,949.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GLAND.NS's P/E ratio is 42.46. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GLAND.NS's ROE of +0.11%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GLAND.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLAND.NS's competition here
Gland Pharma Limited (BSE: GLAND.BO)
AUROPHARMA.NS vs GLAND.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GLAND.BO has a market cap of 480.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GLAND.BO trades at ₹2,949.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GLAND.BO's P/E ratio is 42.50. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GLAND.BO's ROE of +0.11%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GLAND.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLAND.BO's competition here
Ajanta Pharma Limited (NSE: AJANTPHARM.NS)
AUROPHARMA.NS vs AJANTPHARM.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, AJANTPHARM.NS has a market cap of 435.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while AJANTPHARM.NS trades at ₹3,544.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas AJANTPHARM.NS's P/E ratio is 38.42. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to AJANTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AJANTPHARM.NS's competition here
Ajanta Pharma Limited (BSE: AJANTPHARM.BO)
AUROPHARMA.NS vs AJANTPHARM.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, AJANTPHARM.BO has a market cap of 435.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while AJANTPHARM.BO trades at ₹3,533.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas AJANTPHARM.BO's P/E ratio is 38.45. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AJANTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AJANTPHARM.BO's competition here
Suven Pharmaceuticals Limited (NSE: SUVENPHAR.NS)
AUROPHARMA.NS vs SUVENPHAR.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUVENPHAR.NS's competition here
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO)
AUROPHARMA.NS vs SUVENPHAR.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUVENPHAR.BO's competition here
Emcure Pharmaceuticals Ltd. (NSE: EMCURE.NS)
AUROPHARMA.NS vs EMCURE.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, EMCURE.NS has a market cap of 367.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while EMCURE.NS trades at ₹1,904.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas EMCURE.NS's P/E ratio is 35.41. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to EMCURE.NS's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to EMCURE.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check EMCURE.NS's competition here
Neuland Laboratories Limited (BSE: NEULANDLAB.BO)
AUROPHARMA.NS vs NEULANDLAB.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, NEULANDLAB.BO has a market cap of 281B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while NEULANDLAB.BO trades at ₹21,556.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas NEULANDLAB.BO's P/E ratio is 55.57. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to NEULANDLAB.BO's ROE of +0.28%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to NEULANDLAB.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NEULANDLAB.BO's competition here
Neuland Laboratories Limited (NSE: NEULANDLAB.NS)
AUROPHARMA.NS vs NEULANDLAB.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, NEULANDLAB.NS has a market cap of 280.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while NEULANDLAB.NS trades at ₹21,565.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas NEULANDLAB.NS's P/E ratio is 55.46. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to NEULANDLAB.NS's ROE of +0.28%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to NEULANDLAB.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NEULANDLAB.NS's competition here
Piramal Pharma Limited (NSE: PPLPHARMA.NS)
AUROPHARMA.NS vs PPLPHARMA.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, PPLPHARMA.NS has a market cap of 258.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while PPLPHARMA.NS trades at ₹196.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas PPLPHARMA.NS's P/E ratio is -166.41. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to PPLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check PPLPHARMA.NS's competition here
Piramal Pharma Limited (BSE: PPLPHARMA.BO)
AUROPHARMA.NS vs PPLPHARMA.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, PPLPHARMA.BO has a market cap of 257.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while PPLPHARMA.BO trades at ₹197.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas PPLPHARMA.BO's P/E ratio is -166.42. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to PPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check PPLPHARMA.BO's competition here
Piramal Enterprises Limited (NSE: PEL.NS)
AUROPHARMA.NS vs PEL.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check PEL.NS's competition here
Granules India Limited (BSE: GRANULES.BO)
AUROPHARMA.NS vs GRANULES.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GRANULES.BO has a market cap of 203.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GRANULES.BO trades at ₹833.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GRANULES.BO's P/E ratio is 31.23. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GRANULES.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GRANULES.BO's competition here
Granules India Limited (NSE: GRANULES.NS)
AUROPHARMA.NS vs GRANULES.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GRANULES.NS has a market cap of 202.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GRANULES.NS trades at ₹836.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GRANULES.NS's P/E ratio is 31.05. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GRANULES.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GRANULES.NS's competition here
Shilpa Medicare Limited (NSE: SHILPAMED.NS)
AUROPHARMA.NS vs SHILPAMED.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SHILPAMED.NS has a market cap of 201.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SHILPAMED.NS trades at ₹1,058.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SHILPAMED.NS's P/E ratio is 65.51. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SHILPAMED.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SHILPAMED.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SHILPAMED.NS's competition here
Caplin Point Laboratories Ltd. (BSE: CAPLIPOINT.BO)
AUROPHARMA.NS vs CAPLIPOINT.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, CAPLIPOINT.BO has a market cap of 198.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while CAPLIPOINT.BO trades at ₹2,634.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas CAPLIPOINT.BO's P/E ratio is 30.60. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to CAPLIPOINT.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check CAPLIPOINT.BO's competition here
Caplin Point Laboratories Limited (NSE: CAPLIPOINT.NS)
AUROPHARMA.NS vs CAPLIPOINT.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, CAPLIPOINT.NS has a market cap of 197.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while CAPLIPOINT.NS trades at ₹2,652.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas CAPLIPOINT.NS's P/E ratio is 30.60. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to CAPLIPOINT.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check CAPLIPOINT.NS's competition here
Cohance Lifesciences Limited (NSE: COHANCE.NS)
AUROPHARMA.NS vs COHANCE.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, COHANCE.NS has a market cap of 170.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while COHANCE.NS trades at ₹450.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas COHANCE.NS's P/E ratio is 135.12. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to COHANCE.NS's ROE of +0.03%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to COHANCE.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check COHANCE.NS's competition here
Cohance Lifesciences Limited (BSE: COHANCE.BO)
AUROPHARMA.NS vs COHANCE.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, COHANCE.BO has a market cap of 170.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while COHANCE.BO trades at ₹451.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas COHANCE.BO's P/E ratio is 141.15. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to COHANCE.BO's ROE of +0.03%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to COHANCE.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check COHANCE.BO's competition here
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS)
AUROPHARMA.NS vs ALIVUS.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ALIVUS.NS has a market cap of 168.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ALIVUS.NS trades at ₹1,362.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ALIVUS.NS's P/E ratio is 27.23. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ALIVUS.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ALIVUS.NS's competition here
Alivus Life Sciences Limited (BSE: ALIVUS.BO)
AUROPHARMA.NS vs ALIVUS.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ALIVUS.BO has a market cap of 168.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ALIVUS.BO trades at ₹1,365.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ALIVUS.BO's P/E ratio is 27.92. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ALIVUS.BO's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ALIVUS.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ALIVUS.BO's competition here
Eris Lifesciences Limited (NSE: ERIS.NS)
AUROPHARMA.NS vs ERIS.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ERIS.NS has a market cap of 164.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ERIS.NS trades at ₹1,182.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ERIS.NS's P/E ratio is 33.62. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ERIS.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ERIS.NS's competition here
Eris Lifesciences Limited (BSE: ERIS.BO)
AUROPHARMA.NS vs ERIS.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ERIS.BO has a market cap of 164.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ERIS.BO trades at ₹1,181.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ERIS.BO's P/E ratio is 38.49. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ERIS.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ERIS.BO's competition here
Alembic Pharmaceuticals Limited (NSE: APLLTD.NS)
AUROPHARMA.NS vs APLLTD.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, APLLTD.NS has a market cap of 163.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while APLLTD.NS trades at ₹829.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas APLLTD.NS's P/E ratio is 21.76. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check APLLTD.NS's competition here
Alembic Pharmaceuticals Limited (BSE: APLLTD.BO)
AUROPHARMA.NS vs APLLTD.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, APLLTD.BO has a market cap of 163.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while APLLTD.BO trades at ₹828.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas APLLTD.BO's P/E ratio is 21.76. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check APLLTD.BO's competition here
Jubilant Pharmova Limited (BSE: JUBLPHARMA.BO)
AUROPHARMA.NS vs JUBLPHARMA.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, JUBLPHARMA.BO has a market cap of 155.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while JUBLPHARMA.BO trades at ₹984.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas JUBLPHARMA.BO's P/E ratio is 40.68. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to JUBLPHARMA.BO's ROE of +0.05%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to JUBLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check JUBLPHARMA.BO's competition here
Jubilant Pharmova Limited (NSE: JUBLPHARMA.NS)
AUROPHARMA.NS vs JUBLPHARMA.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, JUBLPHARMA.NS has a market cap of 155.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while JUBLPHARMA.NS trades at ₹985.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas JUBLPHARMA.NS's P/E ratio is 40.68. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to JUBLPHARMA.NS's ROE of +0.05%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to JUBLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check JUBLPHARMA.NS's competition here
AstraZeneca Pharma India Limited (BSE: ASTRAZEN.BO)
AUROPHARMA.NS vs ASTRAZEN.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ASTRAZEN.BO has a market cap of 147.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ASTRAZEN.BO trades at ₹5,895.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ASTRAZEN.BO's P/E ratio is 87.15. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ASTRAZEN.BO's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ASTRAZEN.BO's competition here
AstraZeneca Pharma India Limited (NSE: ASTRAZEN.NS)
AUROPHARMA.NS vs ASTRAZEN.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ASTRAZEN.NS has a market cap of 147.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ASTRAZEN.NS trades at ₹5,920.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ASTRAZEN.NS's P/E ratio is 87.09. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ASTRAZEN.NS's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ASTRAZEN.NS's competition here
NATCO Pharma Limited (BSE: NATCOPHARM.BO)
AUROPHARMA.NS vs NATCOPHARM.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, NATCOPHARM.BO has a market cap of 147.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while NATCOPHARM.BO trades at ₹819.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas NATCOPHARM.BO's P/E ratio is 12.87. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to NATCOPHARM.BO's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NATCOPHARM.BO's competition here
Natco Pharma Limited (NSE: NATCOPHARM.NS)
AUROPHARMA.NS vs NATCOPHARM.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, NATCOPHARM.NS has a market cap of 147.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while NATCOPHARM.NS trades at ₹820.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas NATCOPHARM.NS's P/E ratio is 13.54. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to NATCOPHARM.NS's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NATCOPHARM.NS's competition here
Glenmark Life Sciences Limited (NSE: GLS.NS)
AUROPHARMA.NS vs GLS.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLS.NS's competition here
Glenmark Life Sciences Limited (BSE: GLS.BO)
AUROPHARMA.NS vs GLS.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLS.BO's competition here
Sudeep Pharma Ltd. (NSE: SUDEEPPHRM.NS)
AUROPHARMA.NS vs SUDEEPPHRM.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SUDEEPPHRM.NS has a market cap of 132.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SUDEEPPHRM.NS trades at ₹1,177.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SUDEEPPHRM.NS's P/E ratio is 72.57. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUDEEPPHRM.NS's competition here
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS)
AUROPHARMA.NS vs AKUMS.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, AKUMS.NS has a market cap of 122.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while AKUMS.NS trades at ₹812.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas AKUMS.NS's P/E ratio is 42.42. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to AKUMS.NS's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to AKUMS.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AKUMS.NS's competition here
Caplin Point Laboratories Limited (BSE: CAPPL.BO)
AUROPHARMA.NS vs CAPPL.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to CAPPL.BO's ROE of +0.05%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check CAPPL.BO's competition here
Shilpa Medicare Limited (BSE: SHILPAMED.BO)
AUROPHARMA.NS vs SHILPAMED.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SHILPAMED.BO has a market cap of 100.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SHILPAMED.BO trades at ₹1,059.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SHILPAMED.BO's P/E ratio is 67.64. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SHILPAMED.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SHILPAMED.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SHILPAMED.BO's competition here
Strides Pharma Science Limited (NSE: STAR.NS)
AUROPHARMA.NS vs STAR.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, STAR.NS has a market cap of 100.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while STAR.NS trades at ₹1,084.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas STAR.NS's P/E ratio is 16.34. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to STAR.NS's ROE of +0.22%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to STAR.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check STAR.NS's competition here
Viyash Scientific Limited (NSE: VIYASH.NS)
AUROPHARMA.NS vs VIYASH.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, VIYASH.NS has a market cap of 100B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while VIYASH.NS trades at ₹231.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas VIYASH.NS's P/E ratio is 55.06. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to VIYASH.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check VIYASH.NS's competition here
Strides Pharma Science Limited (BSE: STAR.BO)
AUROPHARMA.NS vs STAR.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, STAR.BO has a market cap of 99.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while STAR.BO trades at ₹1,079.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas STAR.BO's P/E ratio is 16.33. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to STAR.BO's ROE of +0.22%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to STAR.BO. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check STAR.BO's competition here
Procter & Gamble Health Limited (BSE: PGHL.BO)
AUROPHARMA.NS vs PGHL.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, PGHL.BO has a market cap of 88.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while PGHL.BO trades at ₹5,247.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas PGHL.BO's P/E ratio is 24.67. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to PGHL.BO's ROE of +0.62%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to PGHL.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check PGHL.BO's competition here
Procter & Gamble Health Limited (NSE: PGHL.NS)
AUROPHARMA.NS vs PGHL.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, PGHL.NS has a market cap of 88B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while PGHL.NS trades at ₹5,269.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas PGHL.NS's P/E ratio is 24.66. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to PGHL.NS's ROE of +0.62%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to PGHL.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check PGHL.NS's competition here
Aarti Pharmalabs Limited (NSE: AARTIPHARM.NS)
AUROPHARMA.NS vs AARTIPHARM.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, AARTIPHARM.NS has a market cap of 85.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while AARTIPHARM.NS trades at ₹977.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas AARTIPHARM.NS's P/E ratio is 40.26. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to AARTIPHARM.NS's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AARTIPHARM.NS's competition here
Aarti Pharmalabs Limited (BSE: AARTIPHARM.BO)
AUROPHARMA.NS vs AARTIPHARM.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, AARTIPHARM.BO has a market cap of 85.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while AARTIPHARM.BO trades at ₹974.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas AARTIPHARM.BO's P/E ratio is 40.28. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to AARTIPHARM.BO's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to AARTIPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AARTIPHARM.BO's competition here
Morepen Laboratories Limited (BSE: MOREPENLAB.BO)
AUROPHARMA.NS vs MOREPENLAB.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, MOREPENLAB.BO has a market cap of 74.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while MOREPENLAB.BO trades at ₹143.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas MOREPENLAB.BO's P/E ratio is 78.21. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to MOREPENLAB.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check MOREPENLAB.BO's competition here
Morepen Laboratories Limited (NSE: MOREPENLAB.NS)
AUROPHARMA.NS vs MOREPENLAB.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, MOREPENLAB.NS has a market cap of 74.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while MOREPENLAB.NS trades at ₹142.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas MOREPENLAB.NS's P/E ratio is 52.75. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to MOREPENLAB.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check MOREPENLAB.NS's competition here
Bliss GVS Pharma Limited (NSE: BLISSGVS.NS)
AUROPHARMA.NS vs BLISSGVS.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, BLISSGVS.NS has a market cap of 70.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while BLISSGVS.NS trades at ₹693.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas BLISSGVS.NS's P/E ratio is 51.64. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check BLISSGVS.NS's competition here
Bliss GVS Pharma Limited (BSE: BLISSGVS.BO)
AUROPHARMA.NS vs BLISSGVS.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, BLISSGVS.BO has a market cap of 70.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while BLISSGVS.BO trades at ₹690.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas BLISSGVS.BO's P/E ratio is 51.31. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check BLISSGVS.BO's competition here
Suven Life Sciences Limited (NSE: SUVEN.NS)
AUROPHARMA.NS vs SUVEN.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SUVEN.NS has a market cap of 69.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SUVEN.NS trades at ₹307.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SUVEN.NS's P/E ratio is -21.50. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SUVEN.NS's ROE of -1.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUVEN.NS's competition here
Suven Life Sciences Limited (BSE: SUVEN.BO)
AUROPHARMA.NS vs SUVEN.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SUVEN.BO has a market cap of 69B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SUVEN.BO trades at ₹307.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SUVEN.BO's P/E ratio is -24.67. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SUVEN.BO's ROE of -1.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUVEN.BO's competition here
Innova Captab Limited (NSE: INNOVACAP.NS)
AUROPHARMA.NS vs INNOVACAP.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, INNOVACAP.NS has a market cap of 65.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while INNOVACAP.NS trades at ₹1,154.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas INNOVACAP.NS's P/E ratio is 53.74. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to INNOVACAP.NS's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to INNOVACAP.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check INNOVACAP.NS's competition here
Sun Pharma Advanced Research Company Limited (NSE: SPARC.NS)
AUROPHARMA.NS vs SPARC.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SPARC.NS has a market cap of 62.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SPARC.NS trades at ₹195.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SPARC.NS's P/E ratio is 4.00. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SPARC.NS's ROE of +3.19%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SPARC.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SPARC.NS's competition here
Sun Pharma Advanced Research Company Limited (BSE: SPARC.BO)
AUROPHARMA.NS vs SPARC.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SPARC.BO has a market cap of 61.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SPARC.BO trades at ₹194.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SPARC.BO's P/E ratio is 3.99. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SPARC.BO's ROE of +3.19%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SPARC.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SPARC.BO's competition here
IOL Chemicals and Pharmaceuticals Limited (NSE: IOLCP.NS)
AUROPHARMA.NS vs IOLCP.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, IOLCP.NS has a market cap of 60.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while IOLCP.NS trades at ₹212.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas IOLCP.NS's P/E ratio is 33.61. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to IOLCP.NS's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check IOLCP.NS's competition here
IOL Chemicals and Pharmaceuticals Limited (BSE: IOLCP.BO)
AUROPHARMA.NS vs IOLCP.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, IOLCP.BO has a market cap of 60.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while IOLCP.BO trades at ₹212.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas IOLCP.BO's P/E ratio is 33.70. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to IOLCP.BO's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check IOLCP.BO's competition here
FDC Limited (BSE: FDC.BO)
AUROPHARMA.NS vs FDC.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, FDC.BO has a market cap of 54B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while FDC.BO trades at ₹335.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas FDC.BO's P/E ratio is 19.18. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to FDC.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check FDC.BO's competition here
FDC Limited (NSE: FDC.NS)
AUROPHARMA.NS vs FDC.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, FDC.NS has a market cap of 53.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while FDC.NS trades at ₹335.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas FDC.NS's P/E ratio is 19.16. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to FDC.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check FDC.NS's competition here
Sequent Scientific Limited (BSE: SEQUENT.BO)
AUROPHARMA.NS vs SEQUENT.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SEQUENT.BO's competition here
Sequent Scientific Limited (NSE: SEQUENT.NS)
AUROPHARMA.NS vs SEQUENT.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SEQUENT.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SEQUENT.NS's competition here
Orchid Pharma Limited (NSE: ORCHPHARMA.NS)
AUROPHARMA.NS vs ORCHPHARMA.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ORCHPHARMA.NS has a market cap of 49B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ORCHPHARMA.NS trades at ₹1,003.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ORCHPHARMA.NS's P/E ratio is 155.79. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ORCHPHARMA.NS's competition here
Orchid Pharma Limited (BSE: ORCHPHARMA.BO)
AUROPHARMA.NS vs ORCHPHARMA.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, ORCHPHARMA.BO has a market cap of 49B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while ORCHPHARMA.BO trades at ₹1,007.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas ORCHPHARMA.BO's P/E ratio is 75.30. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ORCHPHARMA.BO's competition here
Novartis India Limited (BSE: NOVARTIND.BO)
AUROPHARMA.NS vs NOVARTIND.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, NOVARTIND.BO has a market cap of 48.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while NOVARTIND.BO trades at ₹1,995.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas NOVARTIND.BO's P/E ratio is 51.18. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NOVARTIND.BO's competition here
Novartis India Limited (NSE: NOVARTIND.NS)
AUROPHARMA.NS vs NOVARTIND.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, NOVARTIND.NS has a market cap of 48.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while NOVARTIND.NS trades at ₹2,004.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas NOVARTIND.NS's P/E ratio is 51.20. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NOVARTIND.NS's competition here
RPG Life Sciences Limited (BSE: RPGLIFE.BO)
AUROPHARMA.NS vs RPGLIFE.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, RPGLIFE.BO has a market cap of 48.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while RPGLIFE.BO trades at ₹2,918.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas RPGLIFE.BO's P/E ratio is 41.53. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to RPGLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check RPGLIFE.BO's competition here
RPG Life Sciences Limited (NSE: RPGLIFE.NS)
AUROPHARMA.NS vs RPGLIFE.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, RPGLIFE.NS has a market cap of 48B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while RPGLIFE.NS trades at ₹2,925.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas RPGLIFE.NS's P/E ratio is 41.71. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to RPGLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check RPGLIFE.NS's competition here
Gufic Biosciences Limited (NSE: GUFICBIO.NS)
AUROPHARMA.NS vs GUFICBIO.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GUFICBIO.NS has a market cap of 42.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GUFICBIO.NS trades at ₹422.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GUFICBIO.NS's P/E ratio is 58.02. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GUFICBIO.NS's ROE of +0.11%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GUFICBIO.NS's competition here
Gufic Biosciences Limited (BSE: GUFICBIO.BO)
AUROPHARMA.NS vs GUFICBIO.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GUFICBIO.BO has a market cap of 42.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GUFICBIO.BO trades at ₹423.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GUFICBIO.BO's P/E ratio is 57.41. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GUFICBIO.BO's ROE of +0.11%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GUFICBIO.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GUFICBIO.BO's competition here
Gujarat Themis Biosyn Limited (BSE: GUJTHEM.BO)
AUROPHARMA.NS vs GUJTHEM.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GUJTHEM.BO has a market cap of 40.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GUJTHEM.BO trades at ₹377.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GUJTHEM.BO's P/E ratio is 83.45. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GUJTHEM.BO's ROE of +0.18%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GUJTHEM.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GUJTHEM.BO's competition here
Gujarat Themis Biosyn Ltd. (NSE: GUJTHEM.NS)
AUROPHARMA.NS vs GUJTHEM.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, GUJTHEM.NS has a market cap of 40.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while GUJTHEM.NS trades at ₹379.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas GUJTHEM.NS's P/E ratio is 86.41. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to GUJTHEM.NS's ROE of +0.18%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GUJTHEM.NS's competition here
Aarti Drugs Limited (BSE: AARTIDRUGS.BO)
AUROPHARMA.NS vs AARTIDRUGS.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, AARTIDRUGS.BO has a market cap of 37.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while AARTIDRUGS.BO trades at ₹425.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas AARTIDRUGS.BO's P/E ratio is 19.54. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to AARTIDRUGS.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AARTIDRUGS.BO's competition here
Aarti Drugs Limited (NSE: AARTIDRUGS.NS)
AUROPHARMA.NS vs AARTIDRUGS.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, AARTIDRUGS.NS has a market cap of 37.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while AARTIDRUGS.NS trades at ₹425.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas AARTIDRUGS.NS's P/E ratio is 19.53. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to AARTIDRUGS.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AARTIDRUGS.NS's competition here
Unichem Laboratories Limited (BSE: UNICHEMLAB.BO)
AUROPHARMA.NS vs UNICHEMLAB.BO Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, UNICHEMLAB.BO has a market cap of 37.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while UNICHEMLAB.BO trades at ₹546.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas UNICHEMLAB.BO's P/E ratio is 12.28. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to UNICHEMLAB.BO. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check UNICHEMLAB.BO's competition here
Unichem Laboratories Limited (NSE: UNICHEMLAB.NS)
AUROPHARMA.NS vs UNICHEMLAB.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, UNICHEMLAB.NS has a market cap of 37.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while UNICHEMLAB.NS trades at ₹544.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas UNICHEMLAB.NS's P/E ratio is 12.28. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check UNICHEMLAB.NS's competition here
Ind-Swift Laboratories Limited (NSE: INDSWFTLAB.NS)
AUROPHARMA.NS vs INDSWFTLAB.NS Comparison October 2026
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUROPHARMA.NS stands at 963.7B. In comparison, INDSWFTLAB.NS has a market cap of 33.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,688.90 on the NSE, while INDSWFTLAB.NS trades at ₹389.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUROPHARMA.NS currently has a P/E ratio of 26.17, whereas INDSWFTLAB.NS's P/E ratio is 56.55. In terms of profitability, AUROPHARMA.NS's ROE is +0.10%, compared to INDSWFTLAB.NS's ROE of +0.04%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to INDSWFTLAB.NS. This indicates lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check INDSWFTLAB.NS's competition here